The second tranche of a Series C financing round has brought in $20.5 million for Axonics Modulation Technologies, an Irvine, Calif.-based company that makes sacral nerve modulation technology for the treatment of overactive bladder syndrome. The company, which raised $15 million in the first tranche of the round, intends to use the proceeds to support a pivotal study that it will initiate later this year.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.